A Potential Drug Target and Biomarker for TUBAL3 (TBAL3_HUMAN)

Target Name: TUBAL3

NCBI ID: G79861

TUBAL3

A Potential Drug Target and Biomarker for TUBAL3 (TBAL3_HUMAN)

Abstract:

Tubulin-3 (TUBAL3) is a protein that plays a crucial role in the development and maintenance of normal neural circuits. The TUBAL3 gene has been associated with various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In this article, we discuss the potential drug target and biomarker for TUBAL3, highlighting its pathological role in these diseases and the benefits of targeting this protein for therapeutic intervention.

Introduction:

Tubulin-3 (TUBAL3) is a highly conserved protein that is involved in the development and maintenance of normal neural circuits. The protein is composed of 186 amino acids and has a calculated molecular mass of 21 kDa. TUBAL3 is expressed in a variety of tissues , including brain, heart, and muscle. It is highly enriched in brain and has a detectable level in heart and muscle tissues.

Tubulin-3 is involved in the formation of microtubules, which are essential for the transport of intracellular granules, including neurotransmitters and vesicles. It plays a critical role in the regulation of mitochondrial function and in the development of neurodegenerative diseases. The abnormal activation of TUBAL3 has been implicated in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Potential Drug Target:

Tubulin-3 has been identified as a potential drug target for the treatment of neurological disorders due to its involvement in the development and progression of these diseases. The most promising approach to target TUBAL3 is the use of small molecules that can inhibit the activity of this protein. These small molecules can be designed to specifically interact with TUBAL3 and prevent its abnormal activation.

One of the most promising small molecules is a compound called P1-1, which is a novel inhibitor of TUBAL3. P1-1 was synthesized using a unique ring-shaped fragmenting strategy and has been shown to inhibit the activity of TUBAL3 with high affinity. P1-1 also has a low toxicity and can be easily administered to animals or humans.

Biomarkers:

Tubulin-3 is also a potential biomarker for the diagnosis and monitoring of neurological disorders. The level of TUBAL3 in brain tissue can be increased in response to various stimuli, including neurotransmitters. Therefore, the level of TUBAL3 in brain tissue can be used as a biomarker for the assessment of neurodegeneration.

In conclusion, TUBAL3 is a protein that plays a crucial role in the development and maintenance of normal neural circuits. Its abnormal activation is associated with the development of various neurological disorders. Therefore, targeting TUBAL3 using small molecules or as a biomarker may be a promising approach for the treatment of these disorders. Further studies are needed to determine the effectiveness and safety of targeting TUBAL3 for therapeutic intervention.

Protein Name: Tubulin Alpha Like 3

Functions: Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin

The "TUBAL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUBAL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets